# Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

> **NCT03770273** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 21 (actual)

## Conditions studied

- Indolent Systemic Mastocytosis

## Interventions

- **BIOLOGICAL:** sarilumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03770273
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-19
- **Primary completion:** 2023-07-31
- **Final completion:** 2023-07-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03770273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03770273, "Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03770273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*